‘.. S S Advances RNA – Targeted Drug Development Candidate Against PCSK9, an important new target for the treatment of high cholesterol’In addition to further development of SPC5001 in drug development for the treatment of high cholesterol, we remain on track to commence Phase 2 of clinical trials of the miravirsen in patients with hepatitis C in the second half of this year, ‘said Soren Tulstrup, President and Chief Executive Officer, Santaris Pharma A / S.
– Santaris Pharma A / S preclinical data on SPC5001 last month at the PCSK9 Conference From gene to therapeutics in Nantes, France presented, where many of the top pharmaceutical companies gathered efforts to efforts to therapies at inhibiting the important new target PCSK9 , discuss a protein involved in the regulation of LDL or bad cholesterol in the blood.. High cholesterol is a major risk factor for coronary artery disease, According to the World Health Organization, high cholesterol is estimated 18 percent of strokes and 56 percent of heart disease, globally and amounts to about 4.4 million deaths and 40 disability – adjusted life years result .They report that after the adjustment for retirement, the rate of the non-traumatic lower extremities amputations, 3,000 people had diagnosed with diabetes in 2008. Compared a much higher 11.000 in 1996. Coauthor However, in 2008 the rate was some eight times higher than in those with diagnosed diabetes than those without such.
The survey also shows that in the year 2008:prices of leg and the foot amputation of greater men were diagnosed with diabetes than for females to the condition .